Patients suffering from metastatic colorectal cancer (CRC) with the BRAF V600E gene mutation have a poor level of prognosis. The median overall survival of such patients is approximately 4 to 6 months after the failure of initial therapy.
Inhibition of BRAF alone confers limited positive response due to the pathway reactivation through epidermal growth factor receptor signaling. This “MedFact” discusses a research study from the New England Journal Of Medicine, “Response to Encorafenib, Binimetinib, and Cetuximab (EBC) Combination Therapy in BRAF V600E–Mutated Colorectal Cancer" Authors : Kopetz et.al Study in Brief Objective To study the efficacy and overall survival rate of the patients on Encorafenib, Binimetinib, and Cetuximab (EBC) Combination Therapy in BRAF V600E–Mutated Colorectal Cancer Study type Randomized Open-label, phase 3 trial Groups Patients were randomized and…
